Price movement over the last 24 hours
Alcon AG vs ABRDN Physical Gold Shares ETF — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while ABRDN Physical Gold Shares ETF trades at $38.72. The key difference: Alcon AG pays a 0.54% dividend while ABRDN Physical Gold Shares ETF pays none, and ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | SGOL | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $92.22 | $51.41 |
52-Week Low | $62.02 | $31.18 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SGOL, a US-listed gold ETF, trades at $39.65, up 1.04% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights central bank gold buying and shifting Fed rate expectations as key drivers. The stock lacks fundamental ratios like P/E and P/B, typical for commodity ETFs tracking physical gold prices rather than corporate earnings.
The outlook for SGOL hinges on gold's safe-haven appeal amid economic uncertainty, with analysts forecasting potential price gains to $4,600-$5,500 per ounce by 2027. Risks include Fed policy shifts, dollar strength, and volatility from geopolitical events. Investor sentiment is cautiously optimistic due to institutional accumulation and ETF inflows.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →